Journal article
Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection Against Plasmodium falciparum Malaria in Children
V Irani, PA Ramsland, AJ Guy, PM Siba, I Mueller, JS Richards, JG Beeson
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2015
DOI: 10.1093/cid/civ525
Abstract
Background. The targets and mechanisms of human immunity to malaria are poorly understood, which poses a major barrier to malaria vaccine development. Antibodies play a key role in human immunity and may act by inhibiting receptor-binding functions of key merozoite invasion ligands. Antibodies to the major invasion ligand and vaccine candidate, erythrocyte-binding antigen 175 (EBA-175), have been linked with protection, but how these antibodies function has not been established. Methods. We developed 2 new assays that quantify the ability of antibodies to inhibit binding of EBA-175 to its erythrocyte receptor, glycophorin A, using either native or recombinant EBA-175. Binding-inhibitory anti..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council of Australia (grant to J. G. B., Postgraduate Research Fellowship to J. S. R., and Infrastructure for Research Institutes Support Scheme Grant to Burnet Institute); the Australian Research Council (Future Fellowship to J. G. B.); the Victorian State Government Operational Infrastructure Support, University of Melbourne (Melbourne International Fee Remission Scholarship and Melbourne International Research Scholarship to V. I.); and Monash University (Australian Postgraduate Award to A. J. G. and Medicine, Nursing and Health Science International Honours Scholarship to V. I.).